Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients-Reference-Cited by-同舟云学术

Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients

Published:2001-08 Issue:8 Volume:12 Page:1097-1106
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Venturini M.,Michelotti A.,Papaldo P.,Del Mastro L.,Bergaglio M.,Lionetto R.,Lunardi G.,Sguotti C.,Frevola L.,Donati S.,Rosso R.,Cognetti F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/12/8/1097/19479677/12-8-1097.pdf

Reference28 articles.

1. Clinical evaluation of adnamycin, a new antitumor antibiotic;Bonadonna;BMJ,1969

2. Chemotherapy and survival in advanced breast cancer. The inclusion of doxorubicin in Cooper type regimens;A’Hern;Br J Cancer,1993

3. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer;Chan;J Clin Oncol,1999

4. Campos D et al A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC;Nabholtz;Proc Am Soc Clin Oncol,1999

5. Epirubicin, An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer;Coukell;Drugs,1997

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients;Breast Cancer Research and Treatment;2016-03-22

2. Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy;Clinical Pharmacokinetics;2016-03-05

3. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University);Medical Oncology;2013-01-16

4. Inactivation of NF- B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells;Molecular Cancer Therapeutics;2007-10-01

5. Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer;Oncology;2007